Dogwood Therapeutics (DWTX) Net Income towards Common Stockholders (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Net Income towards Common Stockholders of -$5.0 million for Q1 2026, up 59.06% year-over-year from -$3.1 million in Q1 2025, and down 31.91% quarter-over-quarter from -$3.8 million in Q4 2025.
Dogwood Therapeutics (DWTX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$5.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 59.06% year-over-year to -$5.0 million; the TTM figure through Mar 2026 stood at -$28.3 million (down 19.22% YoY), while the FY2025 annual figure was -$35.5 million, down 176.08% from the prior year.
- Net Income towards Common Stockholders slipped to -$5.0 million in Q1 2026 per DWTX's latest filing, from -$3.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$1.0 million in Q2 2024 and bottomed at -$15.7 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged -$4.2 million across 5 years, with a median of -$2.6 million in 2022.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 61.7% — and 2025, when it plunged 843.33%.
- Dogwood Therapeutics' Net Income towards Common Stockholders stood at -$2.0 million in 2022, then jumped by 46.04% to -$1.1 million in 2023, then slumped by 647.12% to -$8.2 million in 2024, then jumped by 54.13% to -$3.8 million in 2025, then slumped by 31.91% to -$5.0 million in 2026.
- Business Quant data shows DWTX's Net Income towards Common Stockholders at -$5.0 million in Q1 2026, -$3.8 million in Q4 2025, and -$15.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | -11.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.99 Mn |
| Dec 31, 2025 | -3.78 Mn |
| Sep 30, 2025 | -15.74 Mn |
| Jun 30, 2025 | -3.81 Mn |
| Mar 31, 2025 | -12.18 Mn |
| Dec 31, 2024 | -8.24 Mn |
| Sep 30, 2024 | -2.28 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | -1.10 Mn |
| Sep 30, 2023 | -1.24 Mn |
| Jun 30, 2023 | -1.44 Mn |
| Mar 31, 2023 | -1.52 Mn |
| Dec 31, 2022 | -2.04 Mn |
| Sep 30, 2022 | -2.58 Mn |
| Jun 30, 2022 | -3.67 Mn |
| Mar 31, 2022 | -3.96 Mn |
| Dec 31, 2021 | -4.51 Mn |
| Sep 30, 2021 | -4.11 Mn |
| Jun 30, 2021 | -4.28 Mn |